细胞治疗在系统性红斑狼疮中的应用

doi:10.35541/cjd.20240520

Abstract

Abstract: 【Abstract】 Systemic lupus erythematosus is a chronic autoimmune disease that affects multiple organs and systems, and current treatment strategies can only result in clinical remission. In recent years, cell therapies have shown promising advancements in the treatment of autoimmune diseases, particularly chimeric antigen receptor technology has demonstrated potential as a transformative therapy for these diseases. This review summarizes the application and prospects of various cell therapies in systemic lupus erythematosus, including hematopoietic stem cell transplantation, mesenchymal stem cell therapy, chimeric antigen receptor-T cell therapy, natural killer cell therapy, and regulatory T cell therapy, aiming to provide insights for optimization and clinical implementation of cell therapies.

Key words: Lupus erythematosus, systemic, Cell therapy, Hematopoietic stem cell transplantation, Mesenchymal stem cells, Chimeric antigen receptor-T cells, Natural killer cells, Regulatory T cells

Lyu Mingyue, Man Xiaoyong. Application of cell therapy in systemic lupus erythematosus[J]. Chinese Journal of Dermatology, 2025, 58(4): 374-377.doi:10.35541/cjd.20240520

References ［32］

［1］	Hoi A, Igel T, Mok CC, et al. Systemic lupus erythematosus［J］. Lancet, 2024,403（10441）:2326⁃2338. doi: 10.1016/S0140⁃6736（24）00398⁃2.
［2］	Ramírez⁃Valle F, Maranville JC, Roy S, et al. Sequential immunotherapy: towards cures for autoimmunity［J］. Nat Rev Drug Discov, 2024,23（7）:501⁃524. doi: 10.1038/s41573⁃024⁃00959⁃8.
［3］	Alexander T, Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party （ADWP） of the European Society for Blood and Marrow Transplantation （EBMT）［J］. Bone Marrow Transplant, 2022,57（7）:1055⁃1062. doi: 10.1038/s41409⁃022⁃01702⁃w.
［4］	Alchi B, Jayne D, Labopin M, et al. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry［J］. Lupus, 2013,22（3）:245⁃253. doi: 10.1177/0961203 312470729.
［5］	Daikeler T, Labopin M, Di Gioia M, et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party［J］. Blood, 2011,118（6）:1693⁃1698. doi: 10.1182/blood⁃2011⁃02⁃336156.
［6］	中华医学会风湿病学分会, 中国医院协会临床新技术应用专业委员会. 异体间充质干细胞治疗系统性红斑狼疮专家共识［J］. 中华风湿病学杂志, 2022,26（1）:1⁃8. doi: 10.3760/cma.j.cn141217⁃20210923⁃00381.
［7］	Xia Y, Ye H, Li K, et al. Efficacy of mesenchymal stem cell therapy on lupus nephritis and renal function in systemic lupus erythematosus: a meta⁃analysis［J］. Clin Invest Med, 2023,46（1）:E24⁃35. doi: 10.25011/cim.v46i1.39561.
［8］	Xu J, Chen J, Li W, et al. Additive therapeutic effects of mesenchymal stem cells and IL⁃37 for systemic lupus erythematosus［J］. J Am Soc Nephrol, 2020,31（1）:54⁃65. doi: 10.1681/ASN.2019050545.
［9］	Zhu HF, Kong B, Nie M, et al. ECM⁃inspired peptide dendrimer microgels with human MSCs encapsulation for systemic lupus erythematosus treatment［J］. Nano Today, 2022,43:101454. doi: 10.1016/j.nantod.2022.101454.
［10］	Zhang M, Johnson⁃Stephenson TK, Wang W, et al. Mesenchymal stem cell⁃derived exosome⁃educated macrophages alleviate systemic lupus erythematosus by promoting efferocytosis and recruitment of IL⁃17+ regulatory T cell［J］. Stem Cell Res Ther, 2022,13（1）:484. doi: 10.1186/s13287⁃022⁃03174⁃7.
［11］	Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19⁃targeted CAR T cells is a highly effective treatment for murine lupus［J］. Sci Transl Med, 2019,11（482）:eaav1648. doi: 10.1126/scitranslmed.aav1648.
［12］	Jin X, Xu Q, Pu C, et al. Therapeutic efficacy of anti⁃CD19 CAR⁃T cells in a mouse model of systemic lupus erythematosus［J］. Cell Mol Immunol, 2021,18（8）:1896⁃1903. doi: 10.1038/s41423⁃020⁃0472⁃1.
［13］	Mougiakakos D, Krönke G, Völkl S, et al. CD19⁃targeted CAR T cells in refractory systemic lupus erythematosus［J］. N Engl J Med, 2021,385（6）:567⁃569. doi: 10.1056/NEJMc2107725.
［14］	Mackensen A, Müller F, Mougiakakos D, et al. Anti⁃CD19 CAR T cell therapy for refractory systemic lupus erythematosus［J］. Nat Med, 2022,28（10）:2124⁃2132. doi: 10.1038/s41591⁃022⁃02017⁃5.
［15］	Müller F, Taubmann J, Bucci L, et al. CD19 CAR T⁃cell therapy in autoimmune disease ⁃ a case series with follow⁃up［J］. N Engl J Med, 2024,390（8）:687⁃700. doi: 10.1056/NEJ Moa2308917.
［16］	Krickau T, Naumann⁃Bartsch N, Aigner M, et al. CAR T⁃cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis［J］. Lancet, 2024,403（10437）:1627⁃1630. doi: 10.1016/S0140⁃6736（24）00424⁃0.
［17］	Wang W, He S, Zhang W, et al. BCMA⁃CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open⁃label clinical trial［J］. Ann Rheum Dis, 2024,83（10）:1304⁃1314. doi: 10.1136/ard⁃2024⁃225785.
［18］	Feng JJ, Hu YX, Chang AH, et al. CD19/BCMA CAR⁃T cell therapy for refractory systemic lupus erythematosus⁃safety and preliminary efficacy data from a phase I clinical study［J］. Blood, 2023, 142 （Suppl 1）: 4835. doi: 10.1182/blood⁃2023⁃186669.
［19］	Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T⁃cell therapy［J］. N Engl J Med, 2024,390（7）:584⁃586. doi: 10.1056/NEJMp2400209.
［20］	Wang X, Wu X, Tan B, et al. Allogeneic CD19⁃targeted CAR⁃T therapy in patients with severe myositis and systemic sclerosis［J］. Cell, 2024,187（18）:4890⁃4904.doi: 10.1016/j.cell. 2024. 06.027.
［21］	Mehta A, Farooq U, Chen A, et al. Interim phase Ⅰ clinical data of FT819⁃101, a study of the first⁃ever, off⁃the⁃shelf, iPSC⁃derived TCR⁃less CD19 CAR T⁃cell therapy for patients with relapsed/refractory B⁃cell malignancies［J］. Blood, 2022,140 （Suppl 1）:4577⁃4578. doi: 10.1182/blood⁃2022⁃167194.
［22］	Rozenbaum M, Meir A, Aharony Y, et al. Gamma⁃delta CAR⁃T cells show CAR⁃directed and independent activity against leukemia［J］. Front Immunol, 2020,11:1347. doi: 10.3389/fimmu.2020.01347.
［23］	Granit V, Benatar M, Kurtoglu M, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T⁃cell therapy in myasthenia gravis （MG⁃001）: a prospective, multicentre, open⁃label, non⁃randomised phase 1b/2a study［J］. Lancet Neurol, 2023,22（7）:578⁃590. doi: 10.1016/S1474⁃4422（23）00194⁃1.
［24］	O'Brien S, Nastoupil LJ, Essell J, et al. A first⁃in⁃human phase 1, multicenter, open⁃label study of CB⁃010, a next⁃generation CRISPR⁃edited allogeneic anti⁃CD19 CAR⁃T cell therapy with a PD⁃1 knockout, in patients with relapsed/refractory B cell non⁃Hodgkin lymphoma （ANTLER study）［J］. Blood, 2022,140 （Suppl 1）:9457⁃9458. doi: 10.1182/blood⁃2022⁃168128.
［25］	Mullard A. In vivo CAR T cells move into clinical trials［J］. Nat Rev Drug Discov, 2024,23（10）:727⁃730. doi: 10.1038/d41573⁃024⁃00150⁃z.
［26］	Sin WX, Jagannathan NS, Teo D, et al. A high⁃density microfluidic bioreactor for the automated manufacturing of CAR T cells［J］. Nat Biomed Eng, 2024,8（12）:1571⁃1591. doi: 10. 1038/s41551⁃024⁃01219⁃1.
［27］	Khanal R, Saultz JN, Farooq U, et al. Trial in progress: AB⁃101, an allogeneic, non⁃engineered, cord blood⁃derived natural killer （NK） cell therapy, as monotherapy or in combination with rituximab in patients with relapsed or refractory non⁃Hodgkin lymphoma［J］. Blood, 2022,140（Suppl 1）:12742⁃12743. doi: 10. 1182/blood⁃2022⁃159282.
［28］	Reighard SD, Cranert SA, Rangel KM, et al. Therapeutic targeting of follicular T cells with chimeric antigen receptor⁃expressing natural killer cells［J］. Cell Rep Med, 2020,1（1）:100003［pii］. doi: 10.1016/j.xcrm.2020.100003.
［29］	Meng H, Sun X, Song Y, et al. La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease［J］. Clin Immunol, 2018,192:40⁃49. doi: 10.1016/j.clim.2018.04.006.
［30］	Dall'Era M, Pauli ML, Remedios K, et al. Adoptive Treg cell therapy in a patient with systemic lupus erythematosus［J］. Arthritis Rheumatol, 2019,71（3）:431⁃440. doi: 10.1002/art. 40737.
［31］	Doglio M, Ugolini A, Bercher⁃Brayer C, et al. Regulatory T cells expressing CD19⁃targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus［J］. Nat Commun, 2024,15（1）:2542. doi: 10.1038/s41467⁃024⁃46448⁃9.
［32］	Eggenhuizen PJ, Cheong R, Lo C, et al. Smith⁃specific regulatory T cells halt the progression of lupus nephritis［J］. Nat Commun, 2024,15（1）:899. doi: 10.1038/s41467⁃024⁃45056⁃x.

[1]	Xu Zhuohong, Hu Yu, Gu Heng. Role of mesenchymal stem cell-derived exosomes in skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220881-e20220881.
[2]	Wang Qi, Jian Zhe. Three-dimensional culture techniques of mesenchymal stem cells and their application in the treatment of skin diseases [J]. Chinese Journal of Dermatology, 2023, 0(2): 20230083-e20230083.
[3]	Wang Guanyu, Wang Yimeng, Li Weiwei, Zhang Chunlei. Novel non-chemotherapeutic treatment options for relapsed/refractory cutaneous T-cell lymphomas [J]. Chinese Journal of Dermatology, 2023, 56(12): 1170-1173.
[4]	Xia Na, Gao Chao, Liu Xuan, Zou Dongxu, Ji Guangju, Cai Hong, . Role of umbilical cord mesenchymal stem cell-derived exosomes in acute skin wound healing [J]. Chinese Journal of Dermatology, 2022, 55(5): 382-388.
[5]	Yu Cong, Zhou Cheng, Zhang Jianzhong. Clinical features of 24 cases of scleroderma-like cutaneous graft-versus-host disease [J]. Chinese Journal of Dermatology, 2022, 55(2): 123-128.
[6]	Wang Xiaoyu, Wang Wenhui, Dai Hui, Xie Jiawei, Wang Guanyu, Guo Jinzhu, Zhang Hua, Wang Xiujuan, Xu Yongsheng, Zhang Chunlei. Therapeutic effect of human umbilical cord mesenchymal stem cells on imiquimod?induced psoriasis-like mouse models [J]. Chinese Journal of Dermatology, 2021, 54(6): 485-492.
[7]	Wang Xiaoyu, Zhang Chunlei, Wang Wenhui. Application of mesenchymal stem cells in psoriasis [J]. Chinese Journal of Dermatology, 2021, 54(11): 1019-1022.
[8]	Wang Pu, Qin Zelian. Autologous fat injection for the treatment of pathological scars [J]. Chinese Journal of Dermatology, 2020, 53(6): 473-475.
[9]	Han Qixin, Niu Xuping, Liu Jia, Qi Ruiqun, Wu Yan. Role of mesenchymal stem cells and their exosomes in Th17/Treg-related pathogenesis of psoriasis [J]. Chinese Journal of Dermatology, 2020, 53(2): 151-154.
[10]	Xing Jianxiao, Liu Yanmin, Li Xiaofang, Li Jiao, Hou Hui, Li Juan, Li Junqin, Zhang Kaiming. Culture and identification of dermal mesenchymal stem cells from skin lesions of patients with psoriasis and analysis of HES1 and CXCL6 expression in these cells [J]. Chinese Journal of Dermatology, 2020, 53(12): 1004-1007.
[11]	Liu Ruifeng, Yang Xiaohong, Liang Jiannan, Zhang Kaiming. Aberrant of circular RNA in mesenchymal stem cells from psoriatic skin lesions [J]. Chinese Journal of Dermatology, 2018, 51(10): 723-728.
[12]	Wu wei . Detection of CD4+CD25+DC127lo/- regulatory T cells in patients with active dermatomyositis [J]. Chinese Journal of Dermatology, 2009, 42(1): 55-56.
[13]	LU Chun, LI Juan, XIONG Wen-jie, GUO Chang-zhan. Treatment of BXSB With Allogeneic Hematopoietic Stem Cell Transplantation [J]. Chinese Journal of Dermatology, 2003, 36(1): 25-27.

Application of cell therapy in systemic lupus erythematosus

PDF

Knowledge

Abstract

Cite this article

share this article

References ［32］

Related Articles 13

Metrics

Comments

Recommended 10